GSK makes academic partnerships in U.S., Canada and Europe
The program offers a new format for scientists to discover drugs through the best resources in the discovery research industry.
Participating scientists must submit details pertaining to the project they are researching. They also must explain with scientific rationale how their early-stage research will assist drug development. The twelve proposals with the best originality, assistance for unmet medical needs, initial progress and strong hypotheses will be chosen for the program.
The chosen scientists will partner with Discovery Partnerships with Academia (DPAc) and Molecular Discovery Research teams, all part of GSK, to examine the results of their hypotheses when met with information about disease pathways and targets that can be found within the library of GSK.
The winning researchers will have the opportunity to work in a formal DPAc partnership, as well as to create new medicine.
“The Discovery Fast Track Challenge is a unique opportunity to integrate the deep biological expertise found in academia with the extensive drug development knowledge of GSK,” Carolyn Buser, the global head of Discovery Partnerships with Academic (DPAc), said. “Winning ideas are translated into a high throughput screen to identify tool compounds for additional proof-of-concept studies. Pending the results and the interests from both academia and GSK, the collaboration may be extended to a long-term partnership to jointly develop therapeutics for the benefit of patients worldwide.”